SFDA Revises China GMP Guidelines; Seeks Industry Comments On Impact To Local Industry
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - China's State FDA revised its Good Manufacturing Practices Guidelines, and is asking for industry feedback on how the guidelines would affect local pharmaceutical companies, SFDA Deputy Director Wu Zhen said during a forum on drug safety and healthcare reform in Beijing April 28
You may also be interested in...
FDA Mulling Whether To Add Unannounced Inspections To Drug Safety Arsenal In China
SAN FRANCISCO - U.S. FDA's newly launched China office is still developing protocols for the country, and the agency is considering adding the use of unannounced inspections to its arsenal of tools crafted to improve product safety and quality
FDA Mulling Whether To Add Unannounced Inspections To Drug Safety Arsenal In China
SAN FRANCISCO - U.S. FDA's newly launched China office is still developing protocols for the country, and the agency is considering adding the use of unannounced inspections to its arsenal of tools crafted to improve product safety and quality
FDA Mulling Whether To Add Unannounced Inspections To Drug Safety Arsenal In China
FDA already has conducted such inspections in India since opening an office there.